<doc>
  <docmeta id="113hr2521ih">
    <bill congress="113" type="hr" number="2521" version="ih"/>
    <revision size="17178" annotations="0" status="complete" id="6" commit-time="2013-07-17T22:42:45Z" committer="mbohmer" doc="113hr2521ih/6.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H1806CD56251A4667BF862DC646C69860" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 2521 IH: Cavernous Angioma Research Resource Act of 2013</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-06-26</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2521</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130626">June 26, 2013</action-date>
			<action-desc>
        <sponsor name-id="L000570">Mr. Ben Ray Luj√°n of New
			 Mexico</sponsor> (for himself, <cosponsor name-id="L000580">Ms. Michelle Lujan
			 Grisham of New Mexico</cosponsor>, and <cosponsor name-id="P000588">Mr.
			 Pearce</cosponsor>) introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to expand and
		  intensify programs of the National Institutes of Health and the Centers for
		  Disease Control and Prevention with respect to translational research and
		  related activities concerning cavernous angioma, and for other
		  purposes.</official-title>
	</form>
	<legis-body id="H676CBEC77F7E48DE91954C64B0BBC0C2" style="OLC">
		<section id="H582597085BCE4261BBE16C8C3F64D566" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Cavernous Angioma Research Resource
			 Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H8B0F97B84D1740FF9BBF893B94343E4B">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> makes the following
			 findings:</text>
			<paragraph id="H2EEFBC3F3BBA4F26B29F16A14647711A">
        <enum>(1)</enum>
        <text>Cavernous angioma,
			 also termed <quote>cerebral cavernous malformations</quote> or
			 <quote>CCM</quote>, affects an estimated 1,500,000 people in the United
			 States.</text>
			</paragraph>
      <paragraph id="H7C1BDD531FBB4E9794772BAC242F17D0">
        <enum>(2)</enum>
        <text>Cavernous angioma
			 is a devastating blood vessel disease that is characterized by the presence of
			 vascular lesions that develop and grow within the brain and spinal cord.</text>
			</paragraph>
      <paragraph id="H0DFC6DE2DDEF432D97F87AB523CC14D8">
        <enum>(3)</enum>
        <text>Detection of
			 cavernous angioma lesions is achieved through costly and specialized medical
			 imaging techniques. These techniques are often not readily available where
			 patients live, and require sedation for children and disabled adults.</text>
			</paragraph>
      <paragraph id="H8DF7DE409076485EB7E65340B9D5818E">
        <enum>(4)</enum>
        <text>Cavernous angioma
			 is a common type of vascular anomaly, but individuals may not be aware that
			 they have the disease until the onset of serious clinical symptoms. In the
			 genetic forms, they may not be aware that it may be passed on to their
			 children.</text>
			</paragraph>
      <paragraph id="H3C0FFE1A5E6C414FA90BA1E37D7B4821">
        <enum>(5)</enum>
        <text>Individuals
			 diagnosed with cavernous angioma may experience neurological deficits, seizure,
			 stroke, or sudden death.</text>
			</paragraph>
      <paragraph id="HB0B6E9D62EB54121B64707FF031759CE">
        <enum>(6)</enum>
        <text>Due to limited
			 research with respect to cavernous angioma, there is no treatment regimen for
			 the disease other than brain and spinal surgery.</text>
			</paragraph>
      <paragraph id="H14F3BD8E8CA54FC08E667A98F29777E1">
        <enum>(7)</enum>
        <text>Some individuals
			 with cavernous angioma are not candidates for brain surgery. No alternative
			 treatment option is available for such individuals.</text>
			</paragraph>
      <paragraph id="H09F0E5F1C899481FB2D0C889E1FB0D50">
        <enum>(8)</enum>
        <text>There is a
			 shortage of physicians who are familiar with cavernous angioma and affected
			 individuals may find it difficult to receive timely diagnosis and appropriate
			 care.</text>
			</paragraph>
      <paragraph id="H30B5405287DE4A3B92871ABD1684C646">
        <enum>(9)</enum>
        <text>Due to the
			 presence of a specific disease-causing mutation, termed the <quote>common
			 Hispanic mutation</quote> that has passed through as many as 17 generations of
			 Americans descended from the original Spanish settlers of the Southwest in the
			 1590s, New Mexico has the highest population density of cavernous angioma in
			 the world. Cavernous angioma affects thousands of individuals in New Mexico and
			 with ancestry in New Mexico.</text>
			</paragraph>
      <paragraph id="H5CD81EF369224FCFA09AF52F0E605841">
        <enum>(10)</enum>
        <text>Other States with
			 high rates of cavernous angioma due to the common Hispanic Mutation include
			 Texas, Arizona, and Colorado.</text>
			</paragraph>
      <paragraph id="H774AF896F6A44620AD3C36B73633665F">
        <enum>(11)</enum>
        <text>To address the
			 public health threat posed by cavernous angioma in New Mexico and throughout
			 the United States, there is a need to identify institutions capable of running
			 clinical trial for this debilitating brain disorder.</text>
			</paragraph>
    </section>
    <section id="H336827D2930943819F4F1D4AD1741549">
      <enum>3.</enum>
      <header>Cavernous angioma
			 research activities</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:IV/pt:B">Part B of
			 title IV of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/284">
            <cato:entity-ref entity-type="uscode" value="usc/42/284/etseq">42 U.S.C. 284 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H1292A22841904A29B5D29E887926D0E3" style="OLC">
				<section id="HDCA3F65EF0DD48CF8CA4797E24059B17">
          <enum>409K.</enum>
          <header>Cavernous
				angioma research activities</header>
					<subsection id="H137A3F3B47354EDF9D6DDBEAAFC1492A">
            <enum>(a)</enum>
            <header>Expansion,
				Intensification, and Coordination of Activities</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of
				NIH</cato:entity-ref>, acting through the director of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institute of Neurological
				Disorders and Stroke</cato:entity-ref>, shall expand and intensify programs of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National
				Institutes of Health</cato:entity-ref> or may award grants and cooperative agreements to public
				or nonprofit private entities (including State health departments, political
				subdivisions of States, universities, and other educational entities) for
				research and related activities concerning cavernous angioma.</text>
					</subsection>
          <subsection id="H3DA628EEA0744E5A84AA3402177B349B">
            <enum>(b)</enum>
            <header>Activities</header>
            <text>In
				expanding and intensifying programs under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:a" proposed="true">subsection (a)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of NIH</cato:entity-ref>
				may carry out the following:</text>
						<paragraph id="HA91DBC7980974B9DA259E310BFC055EC">
              <enum>(1)</enum>
              <header>Basic,
				translational, and clinical research</header>
              <text>Conduct or financially
				support basic, clinical, and translational research on cavernous angioma,
				including research on the following:</text>
							<subparagraph id="HE0BBB5364AD841189B807476D1CE4687">
                <enum>(A)</enum>
                <text>Proteomic,
				pharmacological, and cell biological analysis of the cerebral cavernous
				malformations (referred to in this section as the <quote>CCM</quote>)
				molecules.</text>
							</subparagraph>
              <subparagraph id="H44A11ADB6AE14C4EBBD66A076B77EA0B">
                <enum>(B)</enum>
                <text>Continued
				development and expansion of novel animal models for cavernous angioma
				preclinical research.</text>
							</subparagraph>
              <subparagraph id="HC177AF57550147EC86E33B5EC388B773">
                <enum>(C)</enum>
                <text>Early detection,
				diagnosis, and treatment of cavernous angioma.</text>
							</subparagraph>
              <subparagraph id="HCE9F05AF64E645CDAF2DFF7DE5FAECE0">
                <enum>(D)</enum>
                <text>Biological
				mechanisms for lesion genesis, development, and maturation.</text>
							</subparagraph>
              <subparagraph id="H842D77C8CE3A4FFC83003781F4B16323">
                <enum>(E)</enum>
                <text>Biological
				mechanisms for lesion bleeding and symptomology.</text>
							</subparagraph>
              <subparagraph id="H532D6A3959494C8EA18E01B926C1FFAC">
                <enum>(F)</enum>
                <text>Novel biomedical
				and pharmacological interventions designed to prohibit new lesion development,
				lesion growth, and lesion bleeding.</text>
							</subparagraph>
              <subparagraph id="HD56F3934B0D74829B0C1DB2A79A0767A">
                <enum>(G)</enum>
                <text>Contributions of
				genetic variation to clinical presentation as targets for therapy.</text>
							</subparagraph>
              <subparagraph id="H0FA88C192AFC410EA2FF331D1F5178D0">
                <enum>(H)</enum>
                <text>Identification and
				development of biomarkers to measure phenotypic variation.</text>
							</subparagraph>
              <subparagraph id="H9953F72845FD42FCBA3997699D610DFE">
                <enum>(I)</enum>
                <text>Research related
				to improving the quality of life for individuals with cavernous angioma and
				their families.</text>
							</subparagraph>
              <subparagraph id="H1795C21B58EB402B87C79C06587E8F0F">
                <enum>(J)</enum>
                <text>Clinical training
				programs aimed at increasing the number of scientists and clinicians who are
				trained to treat patients and carry out these research directions.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HB3BD96FE233F469EBC2DEE7996A0AEA2">
              <enum>(2)</enum>
              <header>Facilitation of
				research resources; clinical trial preparedness</header>
							<subparagraph id="HEFE6AE9799B64B43ADF7234E57E10A4B">
                <enum>(A)</enum>
                <header>Coordination</header>
                <text>Identify
				and support the development of a clinical and research coordinating center with
				the potential of coordinating a multi-site clinical drug trial for cavernous
				angioma. Such coordinating center shall provide a model for additional trial
				sites, facilitate medical research to develop a cure for cavernous angioma, and
				enhance the medical care of individuals with cavernous angioma nationwide. Such
				coordinating center shall‚Äî</text>
								<clause id="H8FE22BF30EE8423D93B81DEE6CAB2469">
                  <enum>(i)</enum>
                  <text>have an
				institutional infrastructure that is capable of hosting a clinical trial site
				and facilitating translational projects and collaborations for clinical
				trials;</text>
								</clause>
                <clause id="H8DE23349CD734B49B6C4A418C8165EC3">
                  <enum>(ii)</enum>
                  <text>have the capacity
				to maintain programs dedicated to patient education, patient outreach, and
				awareness, including‚Äî</text>
									<subclause id="H58BBF02153D341EBBC6DF6CFE683FA25">
                    <enum>(I)</enum>
                    <text>launching a
				national multimedia public awareness campaign;</text>
									</subclause>
                  <subclause id="HC2FFBDB4F5FD46AAB11AD094E515D4F6">
                    <enum>(II)</enum>
                    <text>creating and
				distributing patient education materials for distribution by national physician
				and surgeon offices;</text>
									</subclause>
                  <subclause id="H03EDBAD0EC6847B28ABE2D70AE000393">
                    <enum>(III)</enum>
                    <text>establishing an
				education program for elementary and secondary school nurses to facilitate
				early detection and diagnosis of cavernous angioma in areas of high cavernous
				angioma population density;</text>
									</subclause>
                  <subclause id="H567CDF50F272402ABE1C55590F9A76FD">
                    <enum>(IV)</enum>
                    <text>coordinating
				regular patient and family-oriented educational conferences; and</text>
									</subclause>
                  <subclause id="HA36B8304094740C082CE6B7B5123D7B0">
                    <enum>(V)</enum>
                    <text>developing
				nationally relevant electronic health teaching and communication tools and a
				network of professional capacity and patient and family support;</text>
									</subclause>
                </clause>
                <clause id="H578B7CDE8CB64B7AA7BCEB57BF6EAD47">
                  <enum>(iii)</enum>
                  <text>have the
				capacity to establish and maintain communication with other major cavernous
				angioma research and care institutions internationally for information sharing
				and coordination of research activities;</text>
								</clause>
                <clause id="HCBE165BB037D467E8194E550303BB542">
                  <enum>(iv)</enum>
                  <text>have demonstrated
				clinical expertise in cavernous angioma management;</text>
								</clause>
                <clause id="HA90E369879014BD1B2F8BDAB76D00125">
                  <enum>(v)</enum>
                  <text>have a sufficient
				number of eligible patients for participation with particular focus on unique
				subpopulations including Common Hispanic Mutation and CCM3 gene mutation
				carriers; and</text>
								</clause>
                <clause id="H13A895FA7E554B4789E32B2BF2CB307F">
                  <enum>(vi)</enum>
                  <text>have a telehealth
				infrastructure to support and to provide clinical consultation for remote and
				underserved communities.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H024A5133B74944C083F7BEFBC6EC272B">
                <enum>(B)</enum>
                <header>Participation</header>
                <text>Identify
				and support the development of clinical and research participation centers with
				the potential to participate in a multi-site clinical drug trial for cavernous
				angioma. Such participation centers may facilitate medical research to develop
				a cure for cavernous angioma and enhance the medical care of individuals with
				cavernous angioma in partnership with the coordinating center under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> and other national and international centers. Such
				participation centers shall‚Äî</text>
								<clause id="H54AE228D1B05494194710BFAF918F99A">
                  <enum>(i)</enum>
                  <text>have an
				institutional infrastructure capable of hosting a clinical trial site and
				facilitating translational projects and collaborations for clinical
				trials;</text>
								</clause>
                <clause id="HF5E4FF48C168486482EC2194AE81975E">
                  <enum>(ii)</enum>
                  <text>have the capacity
				to maintain communication with other major cavernous angioma research and care
				institutions internationally for information sharing and coordination of
				research activities;</text>
								</clause>
                <clause id="H47739A30D4754A0986CDD41B6571FBEA">
                  <enum>(iii)</enum>
                  <text>have
				demonstrated clinical expertise in cavernous angioma management; and</text>
								</clause>
                <clause id="HDED73DCB1F094035885435329D4DEFE4">
                  <enum>(iv)</enum>
                  <text>have a sufficient
				numbers of eligible patients for participation with particular focus on unique
				subpopulations including Common Hispanic Mutation and CCM3 gene mutation
				carriers as these unique populations may provide insight to other genetic and
				non-genetic forms of the illness.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H43AB114238A748E1A93B706C2ED91EF9">
            <enum>(c)</enum>
            <header>Training program
				for clinicians and scientists</header>
						<paragraph id="HC03CCF513F154B68903B1D5687303A07">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>Eligible coordinating and participation centers under
				this section shall establish or expand training programs for medical and allied
				health clinicians and scientists in clinical practice and research relevant to
				cavernous angioma.</text>
						</paragraph>
            <paragraph id="H1DD713FD71EC451F8211B8D9A7CD2464">
              <enum>(2)</enum>
              <header>Research
				resources</header>
              <text>In carrying out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of NIH</cato:entity-ref>
				may‚Äî</text>
							<subparagraph id="HEA13181301F3467E957AF50391999F43">
                <enum>(A)</enum>
                <text>use information
				collected by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref> pursuant to other provisions of
				law or prior to the date of the enactment of this section;</text>
							</subparagraph>
              <subparagraph id="H37EDBE121F8449C2AA2E644A6FE5A139">
                <enum>(B)</enum>
                <text>take into
				consideration the availability of other research resources;</text>
							</subparagraph>
              <subparagraph id="H25F3F3E803C34377973A45DF6656222A">
                <enum>(C)</enum>
                <text>encourage the use
				of research resources for research on, and development of, therapies and
				treatments for individuals with cavernous angioma; and</text>
							</subparagraph>
              <subparagraph id="H9A8B6B42AB674E0BA64ACF597E0FCD21">
                <enum>(D)</enum>
                <text>encourage the
				inclusion of individuals with cavernous angioma in clinical trials conducted or
				supported by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HB3F9425D604B4D51B197EA2E8C368D2D">
              <enum>(3)</enum>
              <header>Cavernous
				angioma consortium</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of NIH</cato:entity-ref> may provide for the
				participation of agencies of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref> in a consortium
				to facilitate the exchange of information and to make the research effort on
				cavernous angioma more efficient and effective by ensuring consistent
				communication, minimizing duplication of effort, and integrating the varied
				perspectives of partner agencies, organizations, and individuals. Such
				consortium shall include at least one national cavernous angioma patient
				advocacy organization and may be the same consortium receiving a grant or
				contract under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b/p:2/sp:A" proposed="true">subsection
				(b)(2)(A)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H79F58698B6D840719B9728DB72FD8118">
      <enum>4.</enum>
      <header>Centers for
			 Disease Control and Prevention cavernous angioma surveillance and research
			 programs</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:III/pt:B">Part B of title III
			 of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/243">
            <cato:entity-ref entity-type="uscode" value="usc/42/243/etseq">42 U.S.C. 243 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by
			 inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317T">section 317T</cato:entity-ref> the following:</text>
			<quoted-block display-inline="no-display-inline" id="H373778A4658B4EC3A61312FDB60056F3" style="OLC">
				<section id="H9003A56A93884778A5DA15A4238E4431">
          <enum>317U.</enum>
          <header>Cavernous
				angioma surveillance and research programs</header>
					<subsection id="HD1541BB096FB44B1BDFD24A481D8811B">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers
				for Disease Control and Prevention</cato:entity-ref>, may award grants and cooperative agreements
				to public or nonprofit private entities (including State health departments,
				political subdivisions of States, universities, and other educational entities)
				for the collection, analysis, and reporting of data on cavernous angioma. In
				making such awards, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may provide direct technical assistance,
				including personnel support, in lieu of cash.</text>
					</subsection>
          <subsection id="H274B4D14F449496FB171E6C60927EA0F">
            <enum>(b)</enum>
            <header>National
				Cavernous Angioma Epidemiology Program</header>
						<paragraph id="H632B8EF456434B9B869CEA5DC42CE496">
              <enum>(1)</enum>
              <header>Grants</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease Control and
				Prevention</cato:entity-ref>, may award grants to public or nonprofit private entities (including
				State health departments, political subdivisions of States, universities, and
				other educational entities) for the purpose of carrying out epidemiological
				activities regarding cavernous angioma, including collecting and analyzing
				information on the number, incidence, correlates, and symptoms of cases and the
				clinical utility (including costs and benefits) of specific practice patterns.
				In making such awards, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may provide direct technical assistance,
				including personnel support, in lieu of cash.</text>
						</paragraph>
            <paragraph id="HD7B388CB4C1D4227B1D68789A56950DF">
              <enum>(2)</enum>
              <header>National
				surveillance program</header>
              <text>In carrying out <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:a" proposed="true">subsection (a)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall‚Äî</text>
							<subparagraph id="H8DE9B3CBB8B64A1FBBBF6178EED5F8F8">
                <enum>(A)</enum>
                <text>provide for a
				national surveillance program; and</text>
							</subparagraph>
              <subparagraph id="HE06288EBB41B4C3997379B00014E2BFC">
                <enum>(B)</enum>
                <text>where possible,
				ensure that the surveillance program is coordinated with the data and sample
				collection activities of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K" proposed="true">section
				409K</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H64F00BC8BE884A9584B816598F198DE0">
      <enum>5.</enum>
      <header>Food and Drug
			 Administration cavernous angioma clinical trial preparedness and support
			 program</header>
			<subsection id="HFF5BF03ADAB248B18944F5B1F73A2370">
        <enum>(a)</enum>
        <header>Investigational
			 new drug application</header>
        <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and Drugs</cato:entity-ref> shall
			 work with clinical centers, investigators, and advocates to support appropriate
			 investigational new drug application under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:i">section 505(i) of the Federal Food,
			 Drug, and Cosmetic Act</cato:entity-ref> in an effort to hasten the pace of clinical trials for
			 cavernous angioma.</text>
			</subsection>
      <subsection id="H78A4E711AF4B4693ACD72774F5BD2775">
        <enum>(b)</enum>
        <header>Orphan product
			 development</header>
        <text>Where applicable in rare subpopulations of cavernous
			 angioma requiring unique pharmacological intervention, including those with the
			 Common Hispanic Mutation or CCM3 gene mutations, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Commissioner of Food and
			 Drugs</cato:entity-ref> shall support appropriate requests for designations of drugs as orphan
			 drugs under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:526">section 526 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref>.</text>
			</subsection>
    </section>
    <section id="H5711195351984923B39337DE15244450">
      <enum>6.</enum>
      <header>Report to
			 congress</header>
      <text display-inline="no-display-inline">Not later than
			 January 1, 2015, and each January 1 thereafter, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and
			 Human Services</cato:entity-ref> shall prepare and submit to the appropriate committees of the
			 Congress a report concerning the implementation of this Act and the amendments
			 made by this Act.</text>
		</section>
  </legis-body>
</bill>
</doc>